Form 8-K - Current report:
SEC Accession No. 0001628280-24-052539
Filing Date
2024-12-30
Accepted
2024-12-30 07:54:12
Documents
13
Period of Report
2024-12-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K fhtx-20241229.htm   iXBRL 8-K 29726
  Complete submission text file 0001628280-24-052539.txt   156464

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fhtx-20241229.xsd EX-101.SCH 1788
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fhtx-20241229_lab.xml EX-101.LAB 22543
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fhtx-20241229_pre.xml EX-101.PRE 13047
15 EXTRACTED XBRL INSTANCE DOCUMENT fhtx-20241229_htm.xml XML 2829
Mailing Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE SUITE 700 CAMBRIDGE MA 02139 617-586-3100
Foghorn Therapeutics Inc. (Filer) CIK: 0001822462 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39634 | Film No.: 241586963
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)